Furthermore, we discuss novel druggable targets for AF and highlight future directions for clinical trials with drugs directed at DNA damage-PARP1-NAD+ axis with the ultimate aim to preserve quality of life and to attenuate severe complications such as heart failure or stroke in patients with AF. This evidence concerns the gene PARP1 and atrial fibrillation.